Drugs / TRANIMILAST
last change Dec 2025 re-read 2 minutes ago

TRANIMILAST

also known as CHF6001 · Tanimilast · J3.309.618F

Small molecule

Developed for
chronic obstructive pulmonary disease · asthma
Investigated by
Chiesi Farmaceutici S.p.A. · Quintiles, Inc. · SGS S.A.

Trials 17 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 19 trials
Phase 1 NCT06892756 Mar → Jun 2025 chronic obstructive pulmonary disease Chiesi Farmaceutici S.p.A. Completed No outcome recorded
Phase 1 NCT06395610 Mar → Jun 2024 chronic obstructive pulmonary disease Chiesi Farmaceutici S.p.A. Completed No outcome recorded
Phase 1 NCT05431426 Jul → Dec 2022 chronic obstructive pulmonary disease Chiesi Farmaceutici S.p.A. Completed No outcome recorded
Phase 1 NCT05373953 May → Nov 2022 chronic obstructive pulmonary disease Chiesi Farmaceutici S.p.A. Completed No outcome recorded
Phase 1 NCT04756960 Mar → Apr 2021 chronic obstructive pulmonary disease Chiesi Farmaceutici S.p.A. Completed No outcome recorded
Phase 1 NCT04739774 Feb → Apr 2021 chronic obstructive pulmonary disease Chiesi Farmaceutici S.p.A. Completed No outcome recorded
Phase 1 NCT03004495 Jan → Aug 2016 chronic obstructive pulmonary disease Chiesi Farmaceutici S.p.A. Completed No outcome recorded
Phase 1 NCT02386761 Nov 2014 → May 2015 chronic obstructive pulmonary disease Chiesi Farmaceutici S.p.A. Completed No outcome recorded
Phase 1 NCT01703052 Jul 2011 → May 2012 chronic obstructive pulmonary disease Chiesi Farmaceutici S.p.A. Completed No outcome recorded
Phase 26 trials
Phase 2 NCT06900816 Mar → Aug 2025 asthma Chiesi Farmaceutici S.p.A. Completed No outcome recorded
Phase 2 NCT06029595 Nov 2023 → Dec 2025 asthma Chiesi Farmaceutici S.p.A. Terminated No outcome recorded
Phase 2 NCT02986321 Dec 2016 → Oct 2017 chronic obstructive pulmonary disease Chiesi Farmaceutici S.p.A. Completed No outcome recorded
Phase 2 NCT03004417 Oct 2016 → Dec 2017 chronic obstructive pulmonary disease Chiesi Farmaceutici S.p.A. Completed No outcome recorded
Phase 2 NCT01689571 Oct 2012 → Apr 2013 asthma Chiesi Farmaceutici S.p.A. Completed No outcome recorded
Phase 2 NCT01730404 Oct 2012 → Oct 2013 chronic obstructive pulmonary disease Chiesi Farmaceutici S.p.A. Completed No outcome recorded
Phase 32 trials
Phase 3 NCT04636801 Jul 2021 → Oct 2025 chronic obstructive pulmonary disease Chiesi Farmaceutici S.p.A. Terminated No outcome recorded
Phase 3 NCT04636814 Jul 2021 → Dec 2025 chronic obstructive pulmonary disease Chiesi Farmaceutici S.p.A. Terminated No outcome recorded

Evidence & citations 7 cited values

Every value below carries the sentence it was read from. 18 sources stand behind the page.

FieldValueCited text
Known as TRANIMILAST ChEMBL registry synonym — accepted as the source's own label CHEMBL3113974
Known as CHF6001 “Safety, tolerability, and pharmacokinetics of single and repeat ascending doses of CHF6001, a novel inhaled phosphodiesterase-4 inhibitor: two randomized trials in healthy volunteers.” PMID 30425469 Oct 2018
19

“Evaluating the Impact of Hepatic or Renal Impairment on Tanimilast (CHF6001) Pharmacokinetics: Two Open-Label, Parallel-Group, Single-Center Studies.” PMID 40391696 May 2025

“The purpose of this study is to evaluate the amount of the study drug, CHF6001, in the blood of adolescent patients with asthma” NCT06900816

CHF6001 is a novel inhaled phosphodiesterase-4 inhibitor.” PMID 31399091 Aug 2019

CHF6001, an inhaled phosphodiesterase-4 inhibitor” PMID 30425469 Oct 2018

“28-day Inhaled CHF 6001 DPI (1200 µg Daily)” NCT01730404

NCT04636814

NCT04756960

NCT06029595

NCT05373953

NCT01703052

NCT04739774

NCT06900816

NCT06892756

NCT04636801

NCT02986321

NCT01730404

NCT01689571

NCT03004495

NCT06395610

Known as J3.309.618F ChEMBL registry synonym — accepted as the source's own label CHEMBL3113974
Known as Tanimilast “The purpose of this study is to evaluate the efficacy and safety of CHF6001 (Tanimilast) as add-on to maintenance of inhaled corticosteroids in combination with Long-acting...” NCT06029595
6

“The purpose of the study is to evaluate the efficacy and safety of two doses of CHF6001 (Tanimilast), as add-on to maintenance triple therapy in the target patient population.” NCT04636801

Tanimilast is an inhaled phosphodiesterase-4 inhibitor in development for chronic obstructive pulmonary disease and asthma.” PMID 40391696 May 2025

Tanimilast is an inhaled phosphodiesterase-4 inhibitor in development for chronic obstructive pulmonary disease and asthma.” PMID 40391696 May 2025

“Evaluation of the Absolute Bioavailability and Mass Balance of CHF6001 (Tanimilast) in Healthy Subjects” NCT04756960

“Two Doses of CHF6001 DPI (Tanimilast) as add-on to Maintenance Triple Therapy” NCT04636814

“CHF6001 (Tanimilast)” NCT06892756

Action Inhibit “CHF6001, a PDE4 inhibitor” NCT01689571
Modality Small molecule CHEMBL3113974
Route Inhaled “when given by inhalation” NCT01689571